Management of bone metastases in prostate cancer
| Autor: | Marc Bienz, Fred Saad |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology medicine.medical_specialty MEDLINE Antineoplastic Agents Bone Neoplasms Critical Care and Intensive Care Medicine Zoledronic Acid Prostate cancer Quality of life Internal medicine Humans Medicine Radioisotopes Bone Density Conservation Agents Diphosphonates Oncology (nursing) business.industry Advanced stage Imidazoles Prostatic Neoplasms General Medicine medicine.disease Zoledronic acid Denosumab Quality of Life Radiopharmaceuticals business Radium medicine.drug |
| Zdroj: | Current Opinion in Supportive & Palliative Care. 9:261-267 |
| ISSN: | 1751-4258 |
| Popis: | Bone metastases in the advanced stages of prostate cancer have a detrimental effect on the quality of life, resulting in skeletal-related events and pain and place a significant burden on healthcare resources. Improvements in prostate cancer treatment have led to a longer survival of patients. Therefore, quality of life is of growing interest and importance. Successful management and prevention of the complications of bone metastasis in those patients remains, however, clinically challenging.Recently, radium-223 was approved as a treatment for bone metastasis in patients with prostate cancer, joining zoledronic acid, denosumab and other radiopharmaceuticals in the clinical armamentarium. Radium-223 has shown to improve overall survival in patients with bone metastasis.This review focuses on the recent landmark studies on zoledronic acid, denosumab and radium-223 for patients with metastatic prostate cancer and gives a comprehensive overview of their mechanism of action, efficacy, dosage and safety profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|